Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...

Market OverviewThe Global Breast Cancer Therapeutics Market  remains one of the most prevalent forms of cancer worldwide, ...

The "Adalimumab, Infliximab, Etanercept and Trastuzumab Biosimilars Market Opportunities and Strategies to 2033" report has ...

Clarity Pharmaceuticals has added 64/67Cu-SAR-trastuzumab to its Targeted Copper Theranostic (TCT) portfolio, strengthening ...

After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for ...

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: ...

HYDERABAD -Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for a double-digit share in its core U.S. market for its new launches ...

Biocon plans to list its biosimilars business by March 2026 and aims for a double-digit market share in the U.S. for five new biosimilars launching next fiscal year. The U.S. market, already ...

A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while ...

Tocilizumab-anoh is approved for multiple conditions, including rheumatoid arthritis and COVID-19, in intravenous and subcutaneous formulations. Phase 3 study confirmed biosimilarity between ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.